Evogene Ltd. reported third quarter 2025 financial results, highlighting a total operating loss of $8.8 million for the first nine months of 2025, down from $15.3 million in the same period of 2024. Revenues for the nine months ending September 30, 2025, were $3.5 million, compared to $4.0 million in the previous year, mainly due to lower revenue from AgPlenus and a one-time payment from Bayer in 2024, partially offset by increased seed sales from Casterra. Total operating expenses for the third quarter were approximately $2.9 million, down from $6.6 million in Q3 2024. As of September 30, 2025, cash and short-term bank deposits stood at $16.0 million, reflecting proceeds from the sale of Lavie Bio's assets and MicroBoost AI for Ag to ICL. The sale of these assets generated net income of approximately $7.9 million in the third quarter. The company has realigned its organization and reduced costs as part of a strategic shift towards computational chemistry and the generative design of small molecules for pharmaceutical and agricultural industries.